Judit Moldvay

Prof. Dr. Judit Moldvay

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2004 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
Judit MoldvayJudit Moldvay
Judit Moldvay
MJM. Jackel
M. Jackel
KBK. Bogos
K. Bogos
ISI. Soltész
I. Soltész
LAL. Agócs
L. Agócs
ZSZsuzsa Schaff
Zsuzsa Schaff

19 January 2017 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
IMIstván Artúr Molnár
István Artúr Molnár
BMBéla Ákos Molnár
Béla Ákos Molnár
LVLaura Vízkeleti
Laura Vízkeleti
KFKrisztina Fekete
Krisztina Fekete
JTJudit Tamás
Judit Tamás
ATAnna Mária Tőkés
Anna Mária Tőkés

19 April 2018 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
LRLívia Rojkó
Lívia Rojkó
LRLilla Reiniger
Lilla Reiniger
VTVanda Téglási
Vanda Téglási
KFKatalin Fábián
Katalin Fábián
OPOrsolya Anna Pipek
Orsolya Anna Pipek
Judit MoldvayJudit Moldvay
Judit Moldvay

1 August 2007 in Lung Cancer
Verified
Journal Article
Closed access
Judit MoldvayJudit Moldvay
Judit Moldvay
MJMárta Jäckel
Márta Jäckel
CPCsilla Páska
Csilla Páska
ISIbolya Soltész
Ibolya Soltész
ZSZsuzsa Schaff
Zsuzsa Schaff
AKAndrás Kiss
András Kiss

7 July 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KBKristin Breitenecker
Kristin Breitenecker
MHMonika Homolya
Monika Homolya
ALAndreea C. Luca
Andreea C. Luca
VLVeronika Lang
Veronika Lang
CTChristoph Trenk
Christoph Trenk
HMHerwig P. Moll
Herwig P. Moll
Inflammation is a well-known driver of lung tumorigenesis. One strategy by which tumor cells escape tight homeostatic control is by decreasing the expression of the potent anti-inflammatory protein tumor necrosis factor alpha–induced protein 3 (TNFAIP3), also known as A20. We observed that tumor cell intrinsic loss of A20 markedly enhanced lung tumorigenesis and was associated with reduced CD8+ T cell–mediated immune surveillance in patients with lung cancer and in mouse models. In mice, we observed that this effect was completely dependent on increased cellular sensitivity to interferon-γ (IFN-γ) signaling by aberrant activation of TANK-binding kinase 1 (TBK1) and increased downstream expression and activation of signal transducer and activator of transcription 1 (STAT1). Interrupting this autocrine feed forward loop by knocking out IFN-α/β receptor completely restored infiltration of cytotoxic T cells and rescued loss of A20 depending tumorigenesis. Downstream of STAT1, programmed death ligand 1 (PD-L1) was highly expressed in A20 knockout lung tumors. Accordingly, immune checkpoint blockade (ICB) treatment was highly efficient in mice harboring A20-deficient lung tumors. Furthermore, an A20 loss-of-function gene expression signature positively correlated with survival of melanoma patients treated with anti–programmed cell death protein 1. Together, we have identified A20 as a master immune checkpoint regulating the TBK1–STAT1–PD-L1 axis that may be exploited to improve ICB therapy in patients with lung adenocarcinoma.

13 February 2017 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
VTVanda Téglási
Vanda Téglási
LRLilla Reiniger
Lilla Reiniger
KFKatalin Fábián
Katalin Fábián
OPOrsolya Anna Pipek
Orsolya Anna Pipek
ICIrén Csala
Irén Csala
Judit MoldvayJudit Moldvay
Judit Moldvay
Management of lung cancer patients who suffer from brain metastases represents a major challenge. Considering the promising results with immune checkpoint inhibitor treatment, evaluating the status of immune cell (IC) infiltrates in the prognosis of brain metastasis may lead to better therapeutic strategies with these agents. The aim of this study was to characterize the distribution of ICs and determine the expression of the checkpoint molecules programmed death protein 1 (PD-1) and its ligand, PD-L1, in brain metastasis of lung adenocarcinoma (LUAD) patients and to analyze their clinicopathological correlations. We determined the presence of peritumoral mononuclear cells (mononuclear ring) and the density of intratumoral stromal mononuclear cells on brain metastasis tissue sections of 208 LUAD patients. PD-L1/PD-1 expressions were analyzed by immunohistochemistry. Mononuclear rings were significantly associated with better survival after brain metastasis surgery. Cases with massive stromal IC infiltration also showed a tendency for better overall survival. Lower expression of PD-1 and PD-L1 was associated with better survival in patients who underwent surgery for the primary tumor and had multiple brain metastases. Steroid administration and chemotherapy appear not to influence the density of IC in brain metastasis. This is the first study demonstrating the independent prognostic value of mononuclear rings in LUAD cases with brain metastasis. Our results also suggest that the density of tumor-associated ICs in addition to PD-L1 expression of tumor cells and ICs as well as PD-1 expression of ICs may hold relevant information for the appropriate selection of patients who might benefit from anti–PD-L1 or anti–PD-1 therapy.